Evidence map›Paper›PMID 40536685›Full record

ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025

Risk factors for ACL revision failure and optimum graft size for revision anterior cruciate ligament reconstruction.

Victor Yan Zhe Lu, Dennis Hei Yin Lee, Simon Ho Yin Tsui, Thomas Chun Hei Lo, Wai Wang Chau, Annubrat Kumar, Michael Tim Yun Ong, Patrick Shu Hang Yung, Jonathan Patrick Ng

Erratum issuedAbstract read
In one paragraph

Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Victor Yan Zhe LuChinese University of Hong Kong, Sha Tin, Hong Kong, China. victorluwawa@yahoo.com.hk.
Dennis Hei Yin LeeChinese University of Hong Kong, Sha Tin, Hong Kong, China.
Simon Ho Yin TsuiChinese University of Hong Kong, Sha Tin, Hong Kong, China.
Thomas Chun Hei LoChinese University of Hong Kong, Sha Tin, Hong Kong, China.
Wai Wang ChauChinese University of Hong Kong, Sha Tin, Hong Kong, China.
Annubrat KumarChinese University of Hong Kong, Sha Tin, Hong Kong, China.
Michael Tim Yun OngChinese University of Hong Kong, Sha Tin, Hong Kong, China.
Patrick Shu Hang YungChinese University of Hong Kong, Sha Tin, Hong Kong, China.
Jonathan Patrick NgChinese University of Hong Kong, Sha Tin, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGraft re-rupture is a devastating complication after revision ACLR surgery. The literature regarding the risk factors of graft re-rupture is sparse and not definitive. Studies have suggested that a smaller graft diameter is associated with poorer outcomes after primary ACLR, however there is a paucity of literature regarding the effects of graft size on revision ACLR outcomes. This study aims to determine the risk factors for graft re-rupture after revision ACLR, and investigate the optimum graft diameter for revision ACLR.

methodsThe records of all patients who underwent revision ACLR from 2013 to 2021 were reviewed. Data collected included patient demographics, operative variables, and demographic details. To determine the optimal graft diameter, receiver operating characteristic (ROC) analysis was performed. Associations between re-rupture rate and return to pivoting sport, intra-articular knee pathologies, and graft diameter were assessed using contingency tables. Data were examined using univariable logistic regression models to explore the association between graft re-rupture after revision ACLR and prognostic variables. Co-variates with a p value p < 0.100 were included in a multivariable logistic regression model to identify independent associations with graft re-rupture.

resultsIn total, 132 revision ACLR were identified with a mean follow-up time of 3.22 ± 3.26 years. The graft re-rupture rate was 16.7% (n = 22). There were 91 (68.9%) males and 41 (31.1%) female with a mean age of 27.4 years (range 17.3-50.8 years) at revision. 87.9% (n = 116) were involved in one or more types of pivoting sports. Kaplan-Meier analysis showed that the mean survival time for revision ACL grafts was 148 months (95% CI 130-166). The mean graft diameter during revision ACLR was 9.26 mm (range 7.0-10.5 mm) and mean graft length was 43.6 mm (range 22.0-60.0 mm). No associated procedure such as anterolateral (ALL) reconstruction were performed. At the time of revision ACLR, MRI detected concomitant knee pathologies: medial meniscus pathology (n = 45; 34.1%), lateral meniscus pathology (n = 41; 31.1%), chondral pathology (n = 26; 19.7%). None were associated with an increased rate of re-rupture. Risk factors determined by the multivariable logistic regression model were graft diameter < 9 mm (OR: 3.873; 95% CI 1.128-13.293; p = 0.031) and return to pivoting sport after revision ACLR surgery (OR: 4.105; 95%CI 1.008-16.721; p = 0.049).

conclusionA graft diameter < 9 mm and return to pivoting sports after revision ACLR are risk factors for graft re-rupture. Meniscus pathology and chondral lesion were not associated with graft re-rupture. The findings of this study can be used to improve revision ACLR results for patients, but needs to be expanded in multi-centre trials with larger sample sizes.

Indexed as

Anterior Cruciate Ligament InjuriesAnterior Cruciate Ligament ReconstructionReoperationAdolescentAdultFemaleHumansMaleMiddle AgedRetrospective StudiesReturn to SportRisk FactorsTreatment FailureYoung AdultAnterior cruciate ligamentRuptureSports injury

Identifiers

PMID40536685
PMCPMC12179230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.